FDA approves landmark pancreatic cancer drug that's shown to improve survival

The FDA's approval of this new pancreatic cancer drug marks a significant milestone in oncology, providing hope for patients with a particularly aggressive disease that has historically been difficult to treat. By targeting a specific protein that promotes tumor growth, the drug offers a fresh strategy in the fight against pancreatic cancer, potentially extending survival rates. This breakthrough underscores the importance of continued investment in cancer research, as it could lead to more effective treatments and ultimately better outcomes for countless patients.